15:36:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.

Kalender

2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-06-17 12:35:00

Scandinavian ChemoTech AB announces today that the Company has received approval from the European Patent Office. The final injunction for this patent application was announced in a press release on the 3[d ]of February 2021. The examiner announces that the approval will be published 7[th] of July 2021.

The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate.

This innovation provides improved pain control when using the Company's DEEPC™ (Dynamic Electro Enhanced Pain Control) device for IQwave™, for the delivery of electrical pulses to the desired body part.

"A few weeks ago, ChemoTech received CE marking for its medical technology product and system for cancer treatment. It is very gratifying to now also have this EU patent approved, which shows the wide technical range of ChemoTech's TSE platform. We are now expanding the patent protection to also include pain relief, which is a very important part of cancer treatment. This approval gives ChemoTech's human and veterinary operations both the important protection needed for both the commercial establishment in the EU and that it attracts potential partners for distribution and / or licensing agreements. " - says Mohan Frick, CEO and author of this patent together with Prof B Persson